RGC (Regencell) רווח נקי למניה (EPS TTM)

The fragility of Regencell Bioscience (RGC) defensive barriers due to prolonged phytopharmaceutical testing is offset when the 12-month net income per share chart on GURU.Markets includes the fresh parameter -0.02. This resilience is further confirmed by strict government oversight and high entry barriers in neuropharmaceuticals, as well as the synergy of a tight-knit circle of neurology experts united by a unique scientific mission and targeted funding.

Net income per share over 12 months determines the portion of total income attributable to a single security, allowing for an assessment of real capital generation efficiency without accounting for share dilution. By analyzing the net income per share over the last four quarters, an investor compares the financial return against the expenditures of Regencell Bioscience (RGC) on drug synthesis automation and costly clinical trials.